Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, Evans TR, de Bono JS. Lolkema MP, et al. Among authors: mettinger k. Clin Cancer Res. 2011 Feb 1;17(3):581-8. doi: 10.1158/1078-0432.CCR-10-2159. Epub 2010 Nov 24. Clin Cancer Res. 2011. PMID: 21106728 Clinical Trial.
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. Comins C, et al. Among authors: mettinger kl. Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6. Clin Cancer Res. 2010. PMID: 20926400 Free PMC article. Clinical Trial.
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. Karapanagiotou EM, et al. Among authors: mettinger k. Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7. Clin Cancer Res. 2012. PMID: 22316603 Free PMC article. Clinical Trial.
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S. Gollamudi R, et al. Among authors: mettinger k. Invest New Drugs. 2010 Oct;28(5):641-9. doi: 10.1007/s10637-009-9279-8. Epub 2009 Jul 2. Invest New Drugs. 2010. PMID: 19572105 Free PMC article. Clinical Trial.
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program. de Jonge MJ, et al. Among authors: mettinger k. Invest New Drugs. 2004 Aug;22(3):329-33. doi: 10.1023/B:DRUG.0000026260.24275.02. Invest New Drugs. 2004. PMID: 15122081 Clinical Trial.
The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models.
Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A, Tichler T, Shapira J, Bruderman I, Catane R, Kaufman B, Whisnant JK, Mettinger KL, Kalechman Y. Sredni B, et al. Among authors: mettinger kl. Int J Cancer. 1996 Jan 3;65(1):97-103. doi: 10.1002/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F. Int J Cancer. 1996. PMID: 8543404 Clinical Trial.
39 results